Original therapy integrating stem cell tech and gene editing could treat a blood disorder with 350 million carriers worldwide.

Thalassaemia is the world’s most common genetic blood disorder. China currently has 30 million thalassaemia gene carriers, while the global total reaches 350 million. Patient with severe thalassaemia could confront a stark reality: regular blood transfusions, potential organ transplants, and even the risk of premature death. If two carriers of the gene marry, their children have a 25 per cent chance of developing the disease. China’s latest original therapy, which integrates gene editing and…

From China - South China Morning Post via This RSS Feed.